@GoggleDocs

🥽🩺Docs/nurses/pharmacists from U.K. Talking CardioRenoMetabolic & more Catch us on YouTube https://xitter.cf/t.co/VSFSwEDXDD |Educate, Motivate, Activate!

 London, England
Joined October 2020
  • Tweets2.7K
  • Following2.9K
  • Followers3.8K
782Media
Replying to @GoggleDocs @drkevinfernando @drpatrickholmes @scelee1 @DSNforumUK @HannahBeba @CristobMorales
@NICEComms expects benefit in a frail, vulnerable cohort…. Show me the evidence… potential for harm has not been mitigated and needs to be balanced/addressed…
2
1
3
232
💉 Once-weekly basal insulin is here. MHRA has authorised Onswik (efsitora) for #T2D 🏛️NICE: an option, but use the least expensive suitable basal, NPH included. Likely role: people who need help to inject. UK price confidential. Awaiting final TA + ICB pathways. 🔗gov.uk/government/news/mhra-… 🔗frontiersin.org/journals/end…
1
6
11
836
🧓 Can GLP-1 RAs help preserve function in people with diabetes? In 73,592 propensity-matched pairs, GLP-1 RA initiation vs DPP-4 inhibitors was associated with: 📉 Less frailty progression 🚶 13% lower fall rate (IRR 0.87, 95% CI 0.84–0.91) ⚠️ Associations were weaker in severe baseline frailty. Real-world evidence, not proof of causality. #Diabetes #Frailty #GLP1RA #Geriatrics dom-pubs.onlinelibrary.wiley… @AskDrShashank
7
19
640
🩺 HbA1c vs fasting glucose: Which better predicts cardiometabolic multiple long term conditions (multimorbidity) in people without diabetes? Our study led by @scelee1 & Setor In 2,233 adults in England followed for 12–15 years, both markers were associated with future cardiometabolic multimorbidity—but HbA1c was the stronger predictor. 📈 Each 1% higher HbA1c: ~2× higher odds 🔬 HbA1c improved risk discrimination more than fasting glucose. HbA1c help identify long-term cardiometabolic risk earlier? #Diabetes #CardiometabolicHealth #Prevention #PublicHealth sciencedirect.com/science/ar… @AskDrShashank @LDC_tweets @uniofleicester
1
3
11
606
GoggleDocs retweeted
Neil Floch MD
@NeilFlochMDOct 7
GLP-1 are a life changing and possibly a humanity changing group of medications. The fact that insurance will not cover them should cause patients to be extremely angry. Obesity is the mother of chronic disease. Successful obesity treatment should not be discriminated against.
Max Marchione
@maxmarchioneOct 7
It seems that GLP-1s reduce the whole-body risk of disease. Across 5 RCTs, semaglutide lowered blood-based risk scores for diabetes, and in 4 of 5 for AFIB, heart failure and coronary disease. Just fascinating!
7
11
1
53
4,753
GoggleDocs retweeted
Brendon Neuen@brendonneuenOct 8
Colleagues, we need your help - We're seeking nephrologists' perspectives on management of iron deficiency in CKD. The survey takes <5 minutes & will help shape the design of a new international randomised trial rnsapmredcap.nslhd.health.ns… Thanks for sharing with your networks
1
9
18
1,343
Next-Generation Obesity and Diabetes Therapy CagriSema — REIMAGINE 2 HbA1c reduction: 1.9% Weight reduction: 14.6% TIR increased from 52.3% to 88.0% at week 68 Retatrutide — TRIUMPH-2 Major weight reduction with accompanying improvement in glycaemic control. Survodutide — SYNCHRONIZE-2 -Significant weight loss and HbA1c reduction, -gastrointestinal adverse effects ( concerning point) Amylin-Based Therapies -An emerging major pathway for obesity treatment, -cagrilintide and eloralintide. Oral Incretin Therapies -oral semaglutide -orforglipron. Once-Weekly Basal Insulin
2
28
84
3,497
🚨Retatrutide TRIUMPH-1 (NEJM) 80 wk weight: ⤵️25% on 12 mg vs -3.9% placebo. ⤵️28.3% headline = efficacy estimand. 👉9 vs 12 mg near identical; only 54% still on 12 mg at wk 80 ⚠️⚡️Dysaesthesia, hypotension, MACE 9 v 1 (small n) Treat to target, not max dose❓ 🔗 nejm.org/doi/full/10.1056/NE…
2
16
45
1,868
GoggleDocs retweeted
1990sUtd@1990sUtdSep 28
Marvellous edit 😅
75
1,005
155
4,163
851,282
🚨#Tirzepatide and AF: signal or noise? 🫀 🆕 JAHA meta-analysis (10 RCTs, n=6,515): AF OR 2.20 (0.81–6.75), any arrhythmia OR 1.84 (1.04–3.90) 🔹Only 38 AF events, mostly from SUMMIT 🔸Semaglutide: 541 events, OR 0.83 (0.70–0.98) 👉Different class, different signal❓ 🔗ahajournals.org/doi/10.1161/… 🔗academic.oup.com/eurjpc/adva…
1
3
5
602
GoggleDocs retweeted
Don McGowan
@donmcgowanSep 16
Dear @Ofcom Please can you clarify to the nation why this is allowed under your current broadcasting rules? A sitting MP [sometimes] on a TV channel he part owns, delivering a party political broadcast on behalf of Reform UK? Seriously ... WTF?
Reform UK
@reformparty_ukSep 16
Nigel Farage exposes how Labour and the Tories hand out government contracts to their donors. Under Reform UK, contracts will benefit the taxpayer - not our donors.
501
2,129
79
9,933
524,664
🆕NICE guidelines Arguably the biggest shift in #type2diabetes care in over a decade. Phenotype first. HbA1c second. @drkevinfernando & I are running a free hour on what it actually changes in clinic. Thu 10 Sept, 7-8pm BST No industry funding 🔗tickettailor.com/events/oran…
7
12
569
Excited to work with @ATTDconf 👉🏽Management of older adults, technology & diabetes👈🏽 ❓How do we manage older adults with diabetes ❓How do we balance intervention with support and QOL ❓What is the role of technology & how can we simplify/facilitate us02web.zoom.us/webinar/regi…
1
3
10
382
GoggleDocs retweeted
Brendon Neuen@brendonneuenSep 2
“CKD is not really a disease… trials don’t necessarily translate to living longer” Not really sure where to start here. But trials in the last 20 years in which CKD therapies extend survival: #DAPACKD HR 0.69 (0.53-0.88) #FIDELITY HR 0.89 (0.79-1.00) #FLOW HR 0.80 (0.67-0.95)
Anil Makam
@AnilMakamSep 2
Replying to @mvaduganathan
lol. only talking about HF. TOPCAT in my view was positive trial due to fishiness in certain regions. SPIRITHF is harder to reconcile since stopped early. CKD is not really a disease and the outcomes from the trials don't necessarily translate to living better or longer. if you care so much about evidence why not advocate for a head to head trial? why are makers of finenrone and the academics who promote it afraid of elevating the best evidence?
3
8
51
8,288
#ESCcongress2025 💊 STAREE in NEJM: atorvastatin 40mg vs placebo, 9,971 adults aged 70+, 5.9 yrs 📉 Major CV events HR 0.70 ✅ NNT 37 ⚖️ Disability-free survival HR 0.94 (0.84–1.05) ❌ 📊 CV death HR 1.00 Fewer heart attacks. Not a longer or more independent life
2
2
5
588
Interviewed by the @NakedScientists on diabetes related foot wounds @Franers13 @iwgdf @gooday_c thenakedscientists.com/podca…

How can chronic wounds cost more than cancer?

The challenges posed by wounds, and how to treat them

thenakedscientists.com
1
3
460
💊 The 82-year-old on a statin since their 60s. No ASCVD, no symptoms, no evidence either way SAGA/SITE finally randomised it 🔬 📊 3-yr mortality 7.9% continue vs 7.2% stop ✅ Non-inferior (−0.68%, CI −3.95 to 2.60) ❗ No QoL gain from stopping Shared decision, not a rule 🔗thelancet.com/journals/lanhl…
1
9
2
17
1,880
#Obesity care in the #NHS is an absolute and utter shambles Why don’t we just be honest and say we can’t afford any of the drugs till they go generic? Saves lot of people angst. And less said the better about improving conditions to tackle core issues of obesity Either needs new leadership or we need to park it in the “impossible” box and focus on other areas.
10
27
93
5,105
Primary Care The bedrock of #NHS work And this is why I say that primary care leadership has failed within @NHSEngland in the decade or so NHSE has existed If you haven't been able to make the case for increased funding in THE area which does need that? I am afraid the outcomes follow the consequences of your inability to negotiate the funds. So- we are here- where we are. Leadership inactions or failures in a healthcare setting- always has consequences Perhaps never for the individual- yet always for the population. ( Data via @HealthFdn )
8
39
80
4,663
Load more